Pharmaceutical intermediates

Rivaroxaban Intermediates

7 pharmaceutical intermediates for Rivaroxaban. Indication: Pulmonary Embolism; Stroke; Congenital Heart Defect; Thrombosis; Coronary Artery Disease; Coronary Artery Lesion; Peripheral Arterial Disease; Atherosclerosis; Venous Thrombosis; Embolism; Venous Thromboembolism.

提交项目 All intermediates

About Rivaroxaban

Originator: Bayer Healthcare Pharmaceuticals Inc.; Johnson & Johnson Pharmaceutical Research & Development Llc
Indication: Pulmonary Embolism; Stroke; Congenital Heart Defect; Thrombosis; Coronary Artery Disease; Coronary Artery Lesion; Peripheral Arterial Disease; Atherosclerosis; Venous Thrombosis; Embolism; Venous Thromboembolism
Approved Date: 09/30/2008
DS/DP: 08/28/2024

Available intermediates

7 intermediates currently listed for Rivaroxaban. Request specifications, documentation or a quotation for any item below.

Rivaroxaban intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
4-(4-Aminophenyl)morpholin -3-one	438056-69-0	/	/
(S)-(+)-N-(2,3-Epoxypropyl)phthalimide	161596-47-0	/	/
5-Chlorothiophene-2-carboxylic acid	24065-33-6	/	/
5-Chlorothiophene-2-carbonyl chloride	42518-98-9	/	/
2-[[(5S)-2-0x0-3-[4-(3-0xo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-1H-isoindole-1,3(2H)-dione	446292-08-6	/	/
4-[4-[(5S)-5-(Aminomethyl)-2-0xo-3-oxazolidinyl]phenyl] -3-morpholinone hydrochloride	898543-06-1	/	/
2-[(2R)-2-Hydroxy-3-[[4-(3-oxo-4-Morpho linyl)phenyl]aMino]propyl]-1H-isoindole-1 ,3(2H)-dione	446292-07-5	/	/

Other programs under R

Ramelteon Regorafenib Relugolix Remdesivir Remibrutinib Repotrectinib Resmetirom Revumenib

Building toward Rivaroxaban?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →